Spots Global Cancer Trial Database for Well-being in Cancer Patients With Neuropathy During COVID-19 Who Participated in Prior Clinical Trials

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Well-being in Cancer Patients With Neuropathy During COVID-19 Who Participated in Prior Clinical Trials

Official Title: COVID-19: Well-Being in Cancer Patients With Neuropathy Who Participated in Prior Clinical Trials

Study ID: NCT04650178

Conditions

COVID-19 Infection

Hematopoietic and Lymphoid Cell Neoplasm

Malignant Solid Neoplasm

Neuropathy

Interventions

Quality-of-Life Assessment

Questionnaire Administration

Study Description

Brief Summary: This study investigates the experiences of cancer patients with neuropathy during the COVID-19 pandemic to learn how the COVID-19 pandemic affects their quality of life and clinical outcomes. This study will also explore whether there are differences between patients who received neurofeedback (NFB, a type of therapy that is thought to help normalize brain activity) and those who did not. Learning about quality of life in cancer patients with neuropathy during the COVID-19 pandemic may help guide development of programs and policies to improve chronic pain patient care and outcomes during a major global healthcare crisis.

Detailed Description: PRIMARY OBJECTIVES: I. Assess experiences during the coronavirus disease 2019 (COVID-19) pandemic of the health-related quality of life (HRQOL) (e.g. physical, emotional, social well-being), and other COVID-19-specific domains (e.g. anxiety, social interactions, finances), and the associations between COVID-19 experiences and COVID-19-specific distress, HRQOL and clinical outcomes of patients who participated in one of three clinical trials. II. Examine differences in outcomes between neuropathic pain patients who participated in one of two trials of NFB and received NFB, and neuropathic pain patients who participated in a non-treatment-related neuropathy study (i.e., who did not receive NFB). III. Evaluate the extent to which coping and resilience factors moderate the effects of COVID-19 experiences on COVID-19-specific distress, HRQOL and clinical outcomes. OUTLINE: Patients complete an online questionnaire over 15 minutes about their experiences regarding the COVID-19 pandemic including testing, risks of exposure, whether people they know have acquired COVID-19, as well as questions on how the pandemic has impacted their quality of life.